CliffBio
small molecule

LIQREV

SILDENAFIL CITRATE

Loss of exclusivityDecember 2038latest FDA-listed patent expiry
CompanyCMP DEVELOPMENT LLC

Drug detail

Brand nameLIQREV
Active ingredientSILDENAFIL CITRATE
StrengthEQ 10MG BASE/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2023
Marketing statusDISCN

Listed patents

PatentExpiresType
11337979December 2038product
11464778December 2038product
12186321December 2038product
11759468December 2038product
12005062December 2038product

More from CMP DEVELOPMENT LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LIQREV patent cliff — loss of exclusivity December 2038 | CliffBio